Analyst Price Targets — ARDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 10:12 am | Matthew Caufield | H.C. Wainwright | $13.00 | $4.87 | TheFly | Ardelyx price target lowered to $13 from $16 at H.C. Wainwright |
| March 12, 2026 7:10 pm | Roanna Ruiz | Williams Trading | $17.00 | $5.66 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference |
| February 20, 2026 11:07 am | — | H.C. Wainwright | $18.00 | $6.74 | TheFly | Ardelyx price target raised to $18 from $10 at H.C. Wainwright |
| January 27, 2026 11:23 am | — | Jefferies | $15.00 | $7.80 | TheFly | Ardelyx price target raised to $15 from $8 at Jefferies |
| January 9, 2026 10:59 am | Julian Harrison | BTIG | $17.00 | $7.00 | TheFly | Ardelyx price target raised to $17 from $14 at BTIG |
| January 8, 2026 9:34 pm | — | Piper Sandler | $16.00 | $7.00 | TheFly | Ardelyx upgraded to Overweight from Neutral at Piper Sandler |
| January 8, 2026 5:46 pm | Christopher Raymond | Raymond James | $19.00 | $7.00 | TheFly | Ardelyx price target raised to $19 from $16 at Raymond James |
| November 4, 2025 2:10 pm | — | Piper Sandler | $10.00 | $5.86 | TheFly | Ardelyx price target raised to $10 from $9 at Piper Sandler |
| August 5, 2025 1:39 pm | — | Wedbush | $14.00 | $5.13 | TheFly | Ardelyx price target raised to $14 from $13 at Wedbush |
| August 5, 2025 12:40 pm | — | UBS | $12.00 | $5.13 | TheFly | Ardelyx price target raised to $12 from $11 at Raymond James |
Latest News for ARDX
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
Freestone Grove Partners LP bought a new position in Ardelyx, Inc. (NASDAQ: ARDX) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 253,692 shares of the biopharmaceutical company's stock, valued at approximately $1,294,000. Freestone Grove Partners LP owned 0.10% of
Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi &…
Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's s
NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARDX.
U.S. House Trading
No House trades found for ARDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.